Watson G J, Nelson C, Irving R M
Department of Otolaryngology,Head and Neck Surgery,Queen Elizabeth Hospital,Birmingham,UK.
University of Birmingham Medical School,Birmingham,UK.
J Laryngol Otol. 2015 Oct;129(10):970-3. doi: 10.1017/S0022215115002200. Epub 2015 Sep 2.
Since the development of intratympanic aminoglycoside in the 1950s, otologists have been able to chemically ablate the vestibule. We present the results of using low-dose intratympanic gentamicin to treat Ménière's disease.
A retrospective review was performed of all patients who underwent low-dose intratympanic gentamicin therapy over seven years. Data on gender, age, number of procedures, pure tone audiometry and symptom control were analysed.
In all, 38 patients underwent low-dose intratympanic gentamicin therapy. These comprised 25 females and 13 males, with an average age of 58.4 years. Hearing was preserved in 87.5 per cent of patients, with no significant difference before and after treatment (p = 0.744). In all, 85.7 per cent of patients had complete or substantial symptom control (classes A and B, respectively).
Low-dose intratympanic gentamicin therapy was effective in controlling the symptoms of Ménière's disease patients, while preserving hearing.
自20世纪50年代鼓室内注射氨基糖苷类药物问世以来，耳科医生已能够通过化学方法破坏前庭。我们展示了使用低剂量鼓室内注射庆大霉素治疗梅尼埃病的结果。
对七年间接受低剂量鼓室内注射庆大霉素治疗的所有患者进行回顾性研究。分析了性别、年龄、治疗次数、纯音听力测定和症状控制等数据。
共有38例患者接受了低剂量鼓室内注射庆大霉素治疗。其中女性25例，男性13例，平均年龄58.4岁。87.5%的患者听力得以保留，治疗前后无显著差异（p = 0.744）。总体而言，85.7%的患者症状得到完全或显著控制（分别为A类和B类）。
低剂量鼓室内注射庆大霉素疗法在控制梅尼埃病患者症状的同时保留了听力。
